€ million 2016 2015 2014 2013 [2] 2012 [1] [2]
Revenues 49.7 106.2 64.0 78.0 51.9
R&D Expenses 95.7 78.7 56.0 49.2 37.7
SG&A Expenses 14.1 15.1 14.1 18.8 12.1
EBIT -59.9 17.2 -5.9 9.9 2.5
Net Profit/(Loss) -60.4 14.9 -3.0 13.3 1.9
  1. chart-plusCreated with sketchtool. {%group.title%}

    chart-chechmarkCreated with sketchtool. {%groupItem.suffix%}
    {%groupItemData | chartGeneratorNumber%}
  1. chart-plusCreated with sketchtool. {%group.title%}

    Wert In %

    chart-plusCreated with sketchtool. {%groupItem.title%} {%groupItem.suffix%}

    {% groupItem.settings.current | chartGeneratorNumber %} {% groupItem.settings.deviation | chartGeneratorDeviation %}
    5-Jahres-Übersicht
    1. Jahr Wert
      {% groupItem.data[$index] | number %}

[1] Due to the agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the AbD Serotec segment, for the years 2013, 2012 and 2011, revenues, income and expenses in connection with the transaction are shown in the line item “Net Profit/(Loss) from Discontinued Operations.” All other line items consist of amounts from continuing operations.
[2] 2007 to 2012 including employees from the discontinued operations of AbD Serotec.